BG Medicine this week announced that its board of directors has appointed Eric Bouvier as the firm's new president and CEO. The appointment became effective Jan. 9. Bouvier brings more than a decade of experience in the cardiovascular and molecular diagnostic markets. Previously, Bouvier was head of bioMerieux's immunoassay business.

Pieter Muntendam, who has served as president and CEO of BG Medicine for the past six years will now be the company's executive VP and chief medical officer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.